The Amylin Revolution: Why CagriSema and Petrelintide Could Beat GLP-1 on Muscle

GLP-1 receptor agonists changed obesity pharmacology. But they left a problem on the table: 20–40% of the weight people lose on semaglutide or tirzepatide comes from lean mass. For researchers tracking body composition, that’s a significant trade-off. The next class of obesity therapeutics aims to close that gap—and it centers on a hormone most people have never heard of: amylin.

What Is Amylin and Why Does It Matter?

Amylin (islet amyloid polypeptide) is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells after meals. It complements GLP-1 signaling by working through distinct receptors in the area postrema and hypothalamus to:

• Slow gastric emptying via vagal pathways
• Suppress post-meal glucagon secretion
• Enhance satiety through hindbrain signaling (a different circuit than GLP-1)

Pramlintide (Symlin), a first-generation amylin analog, has been FDA-approved for diabetes since 2005. But it required three daily injections and produced modest weight loss (~3–4%). The new generation of long-acting amylin analogs changes the equation entirely.

CagriSema: The Combination That Almost Won

CagriSema pairs cagrilintide 2.4 mg (a long-acting amylin analog) with semaglutide 2.4 mg (the Wegovy active ingredient) in a once-weekly dual-chamber pen. Novo Nordisk filed the NDA in December 2025, with an FDA decision expected by late 2026.

The Phase 3 data tells a nuanced story:

The REDEFINE 4 head-to-head was the market event: CagriSema at 23% vs tirzepatide at 25.5%. Novo Nordisk shares dropped ~15% on the news. But the clinical picture is more nuanced—a 23% weight loss at one injection per week is still remarkable, and Novo is now planning a higher-dose CagriSema trial (2.4/7.2 mg) for H2 2026 with REDEFINE 11 data expected in H1 2027.

The Pipeline Beyond CagriSema

CagriSema isn’t the only amylin story. The pipeline is deep:

• Petrelintide — Zealand Pharma’s long-acting amylin analog, designed as a standalone or add-on to GLP-1s. Pre-clinical data suggests amylin-pathway activation preferentially reduces fat mass over lean mass.
• AZD6234 (APRICUS) — AstraZeneca’s amylin analog in Phase 1. The APRICUS trial is evaluating it as an obesity monotherapy.
• Amycretin — Novo Nordisk’s dual GLP-1/amylin co-agonist (single molecule, not a combination pen). Phase 2 data showed 13% weight loss at just 12 weeks—a trajectory that would exceed CagriSema if it holds.

The Muscle Preservation Question

The core appeal of amylin analogs for the research community is the composition of weight loss, not just the magnitude. Amylin’s satiety mechanism acts through the area postrema and nucleus of the solitary tract—circuits more involved in meal termination than the hypothalamic appetite regulation that GLP-1 dominates. The hypothesis: engaging both pathways simultaneously may reduce compensatory metabolic adaptation and spare lean tissue.

This hasn’t been definitively proven in large human trials. But pre-clinical models of cagrilintide + semaglutide show a higher proportion of fat-to-lean mass loss compared to semaglutide alone. DEXA sub-studies in ongoing CagriSema trials will provide the first large-scale human body-composition data.

What This Means for the Research Landscape

If you’re tracking the obesity pharmacology frontier, amylin analogs are where the puck is heading. The GLP-1 ceiling appears to be 15–20% for monotherapy (semaglutide) and 20–28% for dual-agonists (tirzepatide) to triple-agonists (retatrutide). Amylin opens a third mechanistic axis that stacks on top of existing approaches. Whether that translates to meaningfully better muscle preservation is the billion-dollar question the next two years of data will answer.

Research Peptide Sources

The following vendors ship research-grade peptides with published certificates of analysis. Use code where shown for reader pricing. All products are sold for laboratory and research use only.

Frequently Asked Questions

Related Articles